Progestins (Micronized vs Synthetic): Drug-Drug Interaction Table and Prescribing Guide

What Is the Progestins Drug Class?

Progestins are compounds that bind and activate the progesterone receptor (PR). They fall into two broad groups: micronized progesterone, which is chemically identical to the hormone produced by the corpus luteum and placenta, and synthetic progestins, which are structurally modified molecules engineered for oral bioavailability, longer half-lives, or additional receptor activities. Both groups provide endometrial protection in women with an intact uterus who take estrogen, and both support luteal-phase function in assisted reproduction protocols. The receptor pharmacology and metabolic pathways, however, differ enough that their drug-interaction profiles require separate consideration.

Micronized Progesterone

Oral micronized progesterone (brand name Prometrium in the United States) is FDA-approved at 200 mg nightly for 12 days per cycle as endometrial protection in postmenopausal women taking estrogen, and at 400 mg nightly for 10 days for secondary amenorrhea [1]. Micronization reduces particle size to below 10 microns, dramatically improving intestinal absorption relative to conventional oral progesterone. Even so, oral bioavailability remains approximately 10% due to extensive hepatic first-pass metabolism, primarily via CYP3A4 [2].

The allopregnanolone metabolites generated by that hepatic conversion are positive allosteric modulators of GABA-A receptors. This explains the sedation and dizziness observed at therapeutic doses and creates a clinically meaningful additive interaction with other CNS depressants [3].

Synthetic Progestins: Structural Generations

Synthetic progestins derive from two parent structures. The 19-nortestosterone derivatives include norethindrone, norethindrone acetate, norgestimate, levonorgestrel, and desogestrel. The 17-alpha-hydroxyprogesterone derivatives include medroxyprogesterone acetate (MPA), megestrol acetate, and cyproterone acetate. A newer spironolactone-derived progestin, drospirenone, carries unique antimineralocorticoid activity that creates a distinct interaction with potassium-regulating drugs [4].

Each synthetic agent has varying degrees of androgenic, anti-androgenic, glucocorticoid, or mineralocorticoid activity beyond pure progestogenic effect. Those off-target receptor activities are not just pharmacodynamic footnotes; they directly shape adverse-effect profiles and interaction risks with cardiovascular medications, antidiabetic agents, and anti-androgens.

Metabolic Pathways by Agent

Understanding which enzyme system handles each progestin is the foundation of interaction prediction. No single pathway covers all agents.

CYP3A4-Dominant Agents

Micronized progesterone, norgestimate, desogestrel, and MPA are all metabolized substantially by CYP3A4 [2]. Co-administration of potent CYP3A4 inducers, such as rifampin, carbamazepine, phenytoin, phenobarbital, or St. John's Wort, can reduce plasma concentrations of these progestins by 50% or more. The FDA label for Prometrium explicitly warns that rifampin co-administration is expected to decrease progesterone exposure [1]. For contraceptive progestins in this group, induction may cause contraceptive failure.

Conversely, potent CYP3A4 inhibitors, including ketoconazole, itraconazole, clarithromycin, ritonavir, and grapefruit juice in large quantities, may increase progestin exposure and intensify adverse effects such as sedation (for micronized progesterone) or mood changes.

CYP2C9 and Other Pathways

Norethindrone and levonorgestrel are partially metabolized through CYP2C9 and undergo significant conjugation via sulfotransferases and glucuronosyltransferases [5]. Drugs that induce CYP2C9, such as rifampin and certain anticonvulsants, may accelerate norethindrone clearance. Inhibitors of CYP2C9 (fluconazole, amiodarone, fluvoxamine) could raise norethindrone levels, though the clinical significance is less studied than the CYP3A4 interactions.

P-Glycoprotein and Transporter Involvement

P-glycoprotein (P-gp) influences the intestinal absorption of several progestins. Rifampin is both a CYP3A4 inducer and a P-gp inducer; its interaction with progestins is therefore a dual-mechanism reduction in bioavailability [6]. Clinicians managing patients on rifampin for tuberculosis or Mycobacterium avium complex should assume endometrial protection from low-dose progestins may be inadequate.

Drug-Drug Interaction Table: Progestins vs Major Drug Classes

The table below covers clinically meaningful interactions for the most commonly prescribed progestins in HRT and luteal-support contexts. Severity ratings follow standard pharmacokinetic-pharmacodynamic (PK-PD) classification: Major (avoid or require monitoring and dose adjustment), Moderate (monitor and consider alternatives), Minor (awareness sufficient).

| Interacting Drug / Class | Progestin(s) Affected | Mechanism | Effect | Severity | Clinical Action | |---|---|---|---|---|---| | Rifampin | Micronized progesterone, MPA, norgestimate, levonorgestrel | CYP3A4 + P-gp induction | Up to 50% decrease in progestin AUC | Major | Avoid; use alternative contraception or increase endometrial-protection dose with monitoring | | Carbamazepine, phenytoin, phenobarbital, oxcarbazepine | All CYP3A4-substrate progestins | CYP3A4 induction | Reduced progestin plasma levels | Major | Switch to non-hormonal endometrial protection; barrier contraception | | St. John's Wort (hyperforin >1 mg/day) | All CYP3A4-substrate progestins | CYP3A4 + P-gp induction | Clinically meaningful reduction in exposure | Moderate-Major | Discontinue herbal supplement or use non-hormonal method | | Ketoconazole, itraconazole, voriconazole | Micronized progesterone, MPA | CYP3A4 inhibition | Increased progesterone AUC; enhanced sedation risk | Moderate | Reduce dose if sedation or adverse effects emerge; monitor | | Ritonavir, cobicistat (HIV) | Micronized progesterone, MPA | CYP3A4 inhibition + induction (ritonavir dual effect) | Variable; net effect often increased exposure initially then induction | Moderate-Major | Consult HIV pharmacist; use condoms; avoid relying solely on progestin for contraception | | Benzodiazepines, Z-drugs, opioids | Micronized progesterone | Additive GABA-A potentiation via allopregnanolone metabolite | Increased sedation, psychomotor impairment | Moderate | Dose micronized progesterone at bedtime; counsel on fall risk; avoid in patients with complex sleep medication regimens | | ACE inhibitors, ARBs, potassium-sparing diuretics (spironolactone, eplerenone), NSAIDs | Drospirenone | Drospirenone antimineralocorticoid activity adds to potassium retention | Hyperkalemia risk; serum K+ may rise >5.5 mEq/L | Major | Check serum potassium at baseline and 1 month after initiation; avoid drospirenone in patients with renal impairment or on multiple hyperkalemic agents | | Insulin, sulfonylureas | MPA, high-dose synthetic progestins | Glucocorticoid-like receptor activity impairs insulin sensitivity | Glucose elevation; may increase antidiabetic dose requirements | Moderate | Monitor fasting glucose within 6-8 weeks of initiation; prefer micronized progesterone in patients with diabetes or prediabetes | | Warfarin | Norethindrone acetate, MPA | Possible CYP2C9 competition; modest procoagulant pharmacodynamic effect | Unpredictable INR changes; some progestins may oppose warfarin slightly | Moderate | Monitor INR at 1 and 4 weeks after initiation or dose change | | Fluconazole | Norethindrone, MPA | CYP2C9 + CYP3A4 inhibition | Increased norethindrone or MPA exposure | Moderate | Monitor for adverse effects; single-dose fluconazole 150 mg carries low risk; prolonged courses require monitoring | | Cyclosporine, tacrolimus | Norgestimate, MPA | Shared CYP3A4 metabolism; possible bidirectional competition | Elevated cyclosporine or tacrolimus trough levels | Moderate | Monitor immunosuppressant trough levels after progestin initiation or dose change | | Aprepitant, fosaprepitant (NK1 antagonists) | All CYP3A4-substrate progestins | CYP3A4 induction (early) then inhibition (later) | Biphasic effect on progestin levels | Moderate | Use additional contraception for 28 days after a course of aprepitant | | Bosentan (endothelin antagonist) | All CYP3A4-substrate progestins | CYP3A4 induction | Reduced progestin exposure | Major | Bosentan is teratogenic and also reduces progestin levels; use highly effective non-hormonal contraception | | Lamotrigine | Norethindrone-containing products | Induction of lamotrigine glucuronidation by norethindrone; progestin level also reduced | Lamotrigine levels fall during active pills, rise during pill-free interval; seizure risk | Major | Avoid norethindrone-containing products in lamotrigine-treated epilepsy patients; consult neurology |

Micronized Progesterone vs Synthetic Progestins: Clinical Differentiation

The choice between micronized progesterone and a synthetic agent changes the interaction profile significantly. This section reviews the practical prescribing implications of that choice.

Cardiovascular and Breast Safety Data

The Women's Health Initiative (WHI, N=16,608) demonstrated that conjugated equine estrogen plus MPA increased the risk of invasive breast cancer (hazard ratio 1.26, 95% CI 1.00 to 1.59) and coronary heart disease events compared with placebo [7]. Observational data from the French E3N cohort (N=80,391, mean follow-up 8.1 years) found that postmenopausal women using estrogen combined with micronized progesterone did not have a statistically significant increase in breast cancer risk compared with non-users, while those using synthetic progestins did [8]. The North American Menopause Society 2022 Position Statement states: "Progesterone (micronized) appears to have a more favorable effect on cardiovascular risk markers and possibly breast cancer risk compared with synthetic progestins, though randomized trial data specifically comparing progestogen types remain limited" [9].

Metabolic Effects

MPA and high-dose norethindrone acetate can worsen insulin sensitivity through partial glucocorticoid receptor agonism. A crossover study by Prior et al. Showed that micronized progesterone did not significantly alter fasting glucose or insulin resistance markers over a 12-week treatment period, whereas MPA at 5 mg daily produced a measurable reduction in insulin sensitivity (P<0.05) [10]. For patients with type 2 diabetes or metabolic syndrome, micronized progesterone may be the better-tolerated progestogen when paired with estrogen therapy.

Androgenic Activity and Lipid Effects

Levonorgestrel and norethindrone carry residual androgenic activity that can lower HDL cholesterol by 5 to 15% when used without a concurrent estrogen. Drospirenone, norgestimate, and desogestrel are relatively androgen-neutral or anti-androgenic. Micronized progesterone has essentially no androgenic activity [4]. In patients with dyslipidemia or at cardiovascular risk, androgenic synthetic progestins add an unfavorable lipid signal on top of any estrogen-related changes.

Luteal Support Protocols: DDI Considerations in ART

In assisted reproductive technology (ART), luteal support typically uses vaginal or intramuscular progesterone rather than oral forms, which bypasses first-pass hepatic metabolism and substantially reduces CYP3A4-based interactions [11]. Vaginal progesterone gel (Crinone 8%) or suppositories (200 to 400 mg twice daily) achieve endometrial concentrations via a first-uterine-pass effect while generating lower systemic exposure than oral routes.

A practical DDI-risk stratification framework for progestin selection in luteal support:

1. Patient on enzyme-inducing anticonvulsants (carbamazepine, phenytoin): Use vaginal or intramuscular progesterone to bypass CYP3A4 induction entirely. Do not rely on oral micronized progesterone.
2. Patient on HIV antiretroviral therapy with CYP3A4 inhibitors/inducers (ritonavir, efavirenz): Route matters. Vaginal administration sharply reduces systemic CYP3A4 exposure and is preferred.
3. Patient on drospirenone-containing oral contraceptive transitioning to HRT: If switching to a drospirenone-containing HRT preparation, re-evaluate concurrent potassium-affecting medications and check serum potassium before and 4 weeks after transition.
4. Patient on benzodiazepines or opioids: If oral micronized progesterone is clinically preferred, schedule the dose at bedtime and document fall-risk counseling. Consider vaginal administration as an alternative.
5. Patient on lamotrigine: Avoid norethindrone-containing products. Use micronized progesterone or a non-hormonal option.

Prescribing Guidance: Doses, Formulations, and Monitoring

Endometrial Protection Dosing

For postmenopausal women with an intact uterus taking systemic estrogen, the standard endometrial-protection regimens are [1, 9]:

• Micronized progesterone 200 mg orally each night for 12 to 14 days per 28-day cycle (cyclic regimen)
• Micronized progesterone 100 mg orally each night continuously
• MPA 10 mg orally for 12 to 14 days per cycle (cyclic regimen)
• MPA 2.5 mg orally daily (continuous regimen)
• Norethindrone acetate 0.35 to 1 mg orally daily (continuous)

No progestin should be used for endometrial protection at doses below these thresholds. The FDA label for Prometrium warns specifically against use in patients with peanut allergy, as the capsule formulation contains peanut oil [1].

Vaginal and Intramuscular Formulations

Vaginal progesterone bypasses first-pass metabolism, reducing systemic exposure and the GABA-A sedation effect while achieving high local endometrial concentrations. The first-uterine-pass effect produces endometrial progesterone concentrations 10 to 15 times higher than serum concentrations suggest [12]. Intramuscular progesterone-in-oil (50 mg/mL, given as 25 to 100 mg daily) is still used in many ART centers because serum levels are more predictable, though injection-site pain and sterile abscesses limit long-term tolerability.

Monitoring Parameters

Baseline and follow-up labs depend on the agent selected:

• All patients starting drospirenone: serum potassium, creatinine, and estimated GFR at baseline and at 4 weeks.
• Patients with diabetes starting MPA or high-dose norethindrone: fasting glucose or HbA1c at 8 to 12 weeks.
• Patients on warfarin: INR at 1 week and 4 weeks after progestin initiation or dose change.
• Patients on calcineurin inhibitors (cyclosporine, tacrolimus): trough level within 2 weeks of starting any CYP3A4-competing progestin.
• Patients on lamotrigine: lamotrigine serum level if breakthrough seizures or dose change suspected [13].

Special Populations

Hepatic Impairment

All oral progestins undergo hepatic metabolism. Micronized progesterone and synthetic progestins are generally avoided in severe hepatic impairment (Child-Pugh C). The FDA Prometrium label contraindicates its use in patients with known liver dysfunction or disease [1]. Vaginal progesterone is preferred when progestin therapy is clinically necessary in patients with moderate hepatic impairment, as it minimizes first-pass hepatic load.

Older Adults and Fall Risk

Allopregnanolone-related sedation from micronized progesterone is clinically relevant in adults over 65. The American Geriatrics Society Beers Criteria 2023 does not list micronized progesterone specifically by name but does flag systemic estrogen-progestin combinations as potentially inappropriate in older women outside of specific indications, particularly given CNS effects [14]. When oral micronized progesterone is used in women over 65, bedtime dosing and a fall-risk assessment are both warranted.

Pregnancy and Lactation

Micronized progesterone is used extensively in early pregnancy for luteal support and in women with a history of recurrent pregnancy loss. The PROMISE trial (N=836) showed no statistically significant reduction in live birth rates with vaginal micronized progesterone 400 mg twice daily in women with unexplained recurrent miscarriage (OR 1.04, 95% CI 0.94 to 1.15), though subsequent PRISM trial data (N=4,153) showed benefit in women with early pregnancy bleeding (live birth rate 72% vs 67%, adjusted OR 1.28, P<0.01) [15]. Drug interactions remain relevant in early pregnancy: anticonvulsant co-therapy should prompt vaginal rather than oral progesterone to avoid the CYP3A4 induction effect.

Key Drug Interactions Requiring Immediate Action

Some interactions warrant stopping the current progestin or switching formulations rather than dose adjustment alone. Three scenarios require immediate action:

Rifampin co-administration. Rifampin is one of the most potent combined CYP3A4 and P-gp inducers in clinical use. Even 600 mg rifampin once daily for 7 days has been shown to reduce ethinyl estradiol AUC by approximately 40% and progestin AUC by a comparable margin [6]. Patients starting rifampin for tuberculosis treatment while on progestin-only HRT or contraception should receive explicit counseling that endometrial or contraceptive protection may be inadequate, and an alternative plan documented.

Bosentan. Bosentan is a teratogen and a CYP3A4 inducer. Its co-administration with any hormonal contraceptive containing a progestin is considered contraindicated for contraceptive purposes. The FDA Tracleer label explicitly states that hormonal contraceptives, including oral, injectable, transdermal, and implantable, may not be effective in the presence of bosentan [6, 16].

Lamotrigine plus norethindrone. The norethindrone-lamotrigine bidirectional interaction is unusual. Norethindrone induces lamotrigine glucuronidation, driving lamotrigine serum levels down by 40 to 50% during active progestin days, then sharply up during pill-free or progestin-free intervals. This produces cyclical seizure risk and toxicity [13]. Prescribers should avoid norethindrone-containing products in any patient on lamotrigine for epilepsy, switching to micronized progesterone or a non-hormonal method.